NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class (Descending) | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
67457-0246-01 | 67457-0246 | Octreotide Acetate | Octreotide Acetate | 500.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | April 1, 2011 | In Use | ||
23155-0685-31 | 23155-0685 | Octreotide Acetate | Octreotide Acetate | 200.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | May 25, 2022 | In Use | ||
23155-0686-31 | 23155-0686 | Octreotide Acetate | Octreotide Acetate | 1000.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | May 25, 2022 | In Use | ||
15054-1060-03 | 15054-1060 | Lanreotide acetate | Somatuline Depot | 60.0 mg/.2mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | Nov. 14, 2007 | June 30, 2022 | In Use | |
15054-1060-04 | 15054-1060 | Lanreotide acetate | Somatuline Depot | 60.0 mg/.2mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | Sept. 1, 2019 | In Use | ||
15054-1090-03 | 15054-1090 | Lanreotide acetate | Somatuline Depot | 90.0 mg/.3mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | Nov. 14, 2007 | June 30, 2022 | In Use | |
15054-1090-04 | 15054-1090 | Lanreotide acetate | Somatuline Depot | 90.0 mg/.3mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | Sept. 1, 2019 | In Use | ||
15054-1120-03 | 15054-1120 | Lanreotide acetate | Somatuline Depot | 120.0 mg/.5mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | Nov. 14, 2007 | June 30, 2022 | In Use | |
15054-1120-04 | 15054-1120 | Lanreotide acetate | Somatuline Depot | 120.0 mg/.5mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | Sept. 1, 2019 | In Use | ||
69097-0870-67 | 69097-0870 | Lanreotide acetate | Lanreotide Acetate | 120.0 mg/.5mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | Dec. 24, 2021 | In Use | ||
69097-0880-67 | 69097-0880 | Lanreotide acetate | Lanreotide Acetate | 60.0 mg/.2mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | Dec. 24, 2021 | In Use | ||
69097-0890-67 | 69097-0890 | Lanreotide acetate | Lanreotide Acetate | 90.0 mg/.3mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | Dec. 24, 2021 | In Use | ||
25021-0451-01 | 25021-0451 | Octreotide Acetate | Octreotide Acetate | 50.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Dec. 15, 2013 | In Use | ||
25021-0452-01 | 25021-0452 | Octreotide Acetate | Octreotide Acetate | 100.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Dec. 15, 2013 | Jan. 31, 2023 | In Use | |
25021-0453-01 | 25021-0453 | Octreotide Acetate | Octreotide Acetate | 500.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Dec. 15, 2013 | Feb. 28, 2023 | In Use | |
25021-0454-05 | 25021-0454 | Octreotide Acetate | Octreotide Acetate | 200.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Dec. 15, 2013 | March 31, 2021 | In Use | |
76282-0709-67 | 76282-0709 | Lanreotide acetate | Lanreotide Acetate | 60.0 mg/.2mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | June 1, 2022 | Aug. 18, 2023 | In Use | |
76282-0710-67 | 76282-0710 | Lanreotide acetate | Lanreotide Acetate | 90.0 mg/.3mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | June 1, 2022 | Aug. 18, 2023 | In Use | |
76282-0711-67 | 76282-0711 | Lanreotide acetate | Lanreotide Acetate | 120.0 mg/.5mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | June 1, 2022 | Aug. 18, 2023 | In Use | |
25021-0463-01 | 25021-0463 | Octreotide acetate | Octreotide Acetate | 50.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | June 15, 2023 | In Use | ||
25021-0464-01 | 25021-0464 | Octreotide acetate | Octreotide Acetate | 100.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | June 15, 2023 | In Use | ||
25021-0466-05 | 25021-0466 | Octreotide acetate | Octreotide Acetate | 200.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | June 15, 2023 | In Use | ||
25021-0467-05 | 25021-0467 | Octreotide acetate | Octreotide Acetate | 1000.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | June 15, 2023 | In Use | ||
76282-0718-67 | 76282-0718 | LANREOTIDE ACETATE | LANREOTIDE ACETATE | 60.0 mg/.2mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | May 21, 2024 | In Use | ||
76282-0719-67 | 76282-0719 | LANREOTIDE ACETATE | LANREOTIDE ACETATE | 90.0 mg/.3mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | May 21, 2024 | In Use |
Found 10,000 results in 4 milliseconds — Export these results